ArticleOncology letters2026
Anti-CD20 and -PD-1 antibody effects on proliferation, apoptosis and cell cycle of endometrial cancer cells.
Article in Oncology letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The present study aimed to systematically evaluate the functional effects of the anti-CD20 antibody Rituximab and the programmed cell death 1 (PD-1/PDCD1) antibody Pembrolizumab on endometrial cancer (EC) cells. The expression levels of membrane spanning 4-domains A1 (MS4A1) and PDCD1 in EC tissues and cells were analyzed using the The Cancer Genome Atlas database with R programming language. The impacts of Rituximab and Pembrolizumab treatment on proliferation, apoptosis and cell cycle progression were assessed in Ishikawa and HEC-1A EC cell lines by means of CCK-8 assays and flow cytometry. Both MS4A1 and PDCD1 were significantly upregulated in EC tissues and cells compared with normal controls. Rituximab and Pembrolizumab demonstrated concentration-dependent inhibitory effects on the proliferation of EC cells, induced cell apoptosis and arrested cell cycle progression. Furthermore, the combination of Rituximab and Pembrolizumab resulted in enhanced and more potent suppression of cancer cell growth than either monotherapy alone. In conclusion, the combination of anti-CD20 antibody and PD-1 antibody exerts synergistic antiproliferative effects on EC cells
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.